SHARON ODUM: Open Payments
NPI 1164415949 · FLINT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$433 in 23 payments from 11 companies in 2025. Trend: 2023 $242 · 2024 $318 · 2025 $433
Food & beverage: $433
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 8 | $154 |
| Novo Nordisk Inc | 3 | $58 |
| ABBVIE INC. | 2 | $41 |
| AstraZeneca Pharmaceuticals LP | 2 | $32 |
| E.R. Squibb & Sons, L.L.C. | 2 | $32 |
| Aimmune Therapeutics, Inc. | 1 | $24 |
| GlaxoSmithKline, LLC. | 1 | $22 |
| Exact Sciences Corporation | 1 | $20 |
| Lundbeck LLC | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
Products named: FANAPT, VRAYLAR, Wegovy, REXULTI, COBENFY, ZENPEP, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit.
Industry payments across MI — which companies pay providers there.
